Armistice Capital’s Medifast MED Stock Holding History

Armistice Capital’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24,000	Closed	-$5.32M	–	89
2018 Q3	$5.32M	Buy	+24,000	New	+$4.87M	0.32%	58

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Armistice Capital's MED Position: Q4 2018 in Review

Armistice Capital sold out of Medifast (MED) in Q4 2018, closing a stake of 24,000 shares — an estimated $5.32M sold.

Armistice Capital first reported a position in MED in Q3 2018 and held it in 1 quarter. The position peaked at $5.32M in Q3 2018. 247 funds tracked by Wall St. Rank hold MED as of Q4 2018.

Armistice Capital reported no remaining Medifast position as of Q4 2018 after selling out during the quarter.
Armistice Capital sold 24,000 Medifast shares in Q4 2018, an estimated $5.32M.
Armistice Capital first reported a position in Medifast in Q3 2018 and held it in 1 quarter.
Armistice Capital's Medifast position peaked at $5.32M in Q3 2018.
247 funds tracked by Wall St. Rank held Medifast as of Q4 2018.

Based on Armistice Capital's 13F filing for Q4 2018, filed 14 Feb 2019.